Korro Bio, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
KRRO$15.73+5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(amounts in thousands, except share amounts)
| Common Stock · AdditionalPaid- · AccumulatedOtherComprehensive · Accumulated · TotalStockholders' | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | In Capital | Income (Loss) | Deficit | Equity | |
| Balance at December 31, 2024 | 9,377,259 | $9 | $426,724 | $268 | $(266,586) | $160,415 |
| Exercises of stock options | 11,643 | — | 172 | — | — | 172 |
| Stock-based compensation expense | — | — | 1,761 | — | — | 1,761 |
| Other comprehensive loss, net of tax of $0 | — | — | — | (4) | — | (4) |
| Net loss | — | — | — | — | (23,387) | (23,387) |
| Balance at March 31, 2025 | 9,388,902 | $9 | $428,657 | $264 | $(289,973) | $138,957 |
| Exercises of stock options | 1,940 | — | 5 | — | — | 5 |
| Stock-based compensation expense | — | — | 1,998 | — | — | 1,998 |
| Other comprehensive loss, net of tax of $0 | — | — | — | (87) | — | (87) |
| Net loss | — | — | — | — | (25,770) | (25,770) |
| Balance at June 30, 2025 | 9,390,842 | $9 | $430,660 | $177 | $(315,743) | $115,103 |
| Exercises of stock options | 7,142 | — | 128 | — | — | 128 |
| Stock-based compensation expense | — | — | 1,825 | — | — | 1,825 |
| Other comprehensive income, net of tax of $0 | — | — | — | 37 | — | 37 |
| Net loss | — | — | — | — | (18,061) | (18,061) |
| Balance at September 30, 2025 | 9,397,984 | $9 | $432,613 | $214 | $(333,804) | $99,032 |
| Balance at December 31, 2023 | 8,016,516 | $8 | $352,908 | $— | $(183,005) | $169,911 |
| Exercises of stock options | 5,947 | — | 139 | — | — | 139 |
| Stock-based compensation expense | — | — | 865 | — | — | 865 |
| Net loss | — | — | — | — | (19,557) | (19,557) |
| Balance at March 31, 2024 | 8,022,463 | $8 | $353,912 | $— | $(202,562) | $151,358 |
| Exercises of stock options | 8,191 | — | 172 | — | — | 172 |
| Stock-based compensation expense | — | — | 967 | — | — | 967 |
| Issuance of common stock for cash in PIPE financing | 1,249,283 | 1 | 67,384 | — | — | 67,385 |
| Unrealized gain on investments, net of tax of $0 | — | — | — | 21 | — | 21 |
| Net loss | — | — | — | — | (21,826) | (21,826) |
| Balance at June 30, 2024 | 9,279,937 | $9 | $422,435 | $21 | $(224,388) | $198,077 |
| Exercises of stock options | 38,419 | — | 728 | — | — | 728 |
| Stock-based compensation expense | — | — | 1,273 | — | — | 1,273 |
| Unrealized gain on investments, net of tax of $0 | — | — | — | 553 | — | 553 |
| Net loss | — | — | — | — | (20,999) | (20,999) |
| Balance at September 30, 2024 | 9,318,356 | $9 | $424,436 | $574 | $(245,387) | $179,632 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.